Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “cells”

914 pharma patents match "cells" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 914
Index total 30,257
Page 5 / 39

Quick answer

This filtered view shows 914 pharmaceutical patents matching "cells" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

914 results for “cells” · 30,257 patents in full index Clear search

  1. US 11913027

    Methods of treatment using pluripotent human adipose adult stem cells

    The Regents of the University of California · Granted Feb 27, 2024 · Expires Feb 22, 2044

    granted
  2. US 11903973

    Genetically engineered hematopoietic stem cells and uses thereof

    Vor Biopharma Inc. · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  3. US 11903967

    Method of preparing T cells with increased activity

    AUTOLUS LIMITED · Granted Feb 20, 2024 · Expires Feb 15, 2044

    granted
  4. US 11898166

    In vitro generation of thymic organoid from human pluripotent stem cells

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  5. US 11898165

    Engineered host cells and methods of use thereof

    MiNK Therapeutics, Inc. · Granted Feb 13, 2024 · Expires Feb 8, 2044

    granted
  6. US 11891628

    Method for biomimetic culture of urothelial cells and uses thereof

    China Medical University · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  7. US 11891626

    Isolated discogenic cells, methods of using, and methods of preparing same from mammalian tissue

    DiscGenics, Inc. · Granted Feb 6, 2024 · Expires Feb 1, 2044

    granted
  8. US 11885807

    Method for depleting malignant T-cells

    AUTOLUS LIMITED · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  9. US 11884932

    In vitro production of medial ganglionic eminence precursor cells

    The Regents of the University of California · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  10. US 11883431

    T-cells modified to overexpress PHF19

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  11. US 11885806

    Method for depleting malignant T-cells

    AUTOLUS LIMITED · Granted Jan 30, 2024 · Expires Jan 25, 2044

    granted
  12. US 11865157

    Compositions and methods of targeting cancer stem cells

    The Board of Regents of the University of Texas System · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  13. US 11866794

    Cas-ready mouse embryonic stem cells and mice and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 9, 2024 · Expires Jan 4, 2044

    granted
  14. US 11858884

    Compositions and methods for modulating gene or gene product in cells

    The Board of Regents of the University of Texas System · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  15. US 11857574

    Genetically engineered T cells with Regnase-1 and/or TGFBRII disruption have improved functionality and persistence

    CRISPR THERAPEUTICS AG · Granted Jan 2, 2024 · Expires Dec 28, 2043

    granted
  16. US 11851680

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Precision BioSciences, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  17. US 11851672

    CAR T-cells comprising transcriptional circuits

    AUTOLUS LIMITED · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  18. US 11850261

    Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

    Astellas Institute for Regenerative Medicine · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  19. US 11851677

    Composition and methods for inducing myeloid suppressive cells and use thereof

    Fate Therapeutics, Inc. · Granted Dec 26, 2023 · Expires Dec 21, 2043

    granted
  20. US 11839631

    Treatment of pulmonary arterial hypertension with prostacyclin-treated endothelial progenitor cells

    United Therapeutics Corporation · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  21. US 11839596

    Treatment of vasculopathy with prostacyclin and mesenchymal stem cells

    United Therapeutics Corporation · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  22. US 11840575

    Engineered immune cells targeting BCMA and their uses thereof

    GRACELL BIOTECHNOLOGIES (SHANGHAI) CO., LTD. · Granted Dec 12, 2023 · Expires Dec 7, 2043

    granted
  23. US 11801265

    Preparation method of NK cells and use thereof in the treatment of cancer

    SINO UNITED (BEIJING) BIOMEDICAL TECHNOLOGY CO., LTD. · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted
  24. US 11802272

    Enrich and amplify highly potent human mesenchymal stem cells from elderly cell populations

    The Board of Regents of the University of Texas System · Granted Oct 31, 2023 · Expires Oct 26, 2043

    granted